# VNX-101

Source: https://onco.cc/drugs/vnx-101/  
OnCo record `vnx-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VNX-101 is an experimental in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics, in phase 1 trials for CD19-positive B-cell acute lymphoblastic leukaemia, B-cell lymphomas and chronic lymphocytic leukaemia.

## Summary

VNX-101 (AAV.CD3/CD19) is an in vivo gene therapy: AAV vector encoding a bispecific T-cell engager from Vironexis Biotherapeutics. A single intravenous dose of an adeno-associated virus vector that makes the liver secrete a CD3 x CD19 bispecific T-cell engager continuously. Its furthest stage is phase 1, for CD19-positive B-cell acute lymphoblastic leukaemia, B-cell lymphomas (large B-cell, follicular, mantle cell, marginal zone, Burkitt) and chronic lymphocytic leukaemia. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 SENTRY-CD19 NCT06533579 recruiting. The company lists FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: AAV.CD3/CD19
- Tags: pipeline; ctgov-ingest
- Code: VNX-101
- Modality: In vivo gene therapy: AAV vector encoding a bispecific T-cell engager
- Mechanism: A single intravenous dose of an adeno-associated virus vector that makes the liver secrete a CD3 x CD19 bispecific T-cell engager continuously.

## Sources

- Vironexis Biotherapeutics: vironexis.com: https://vironexis.com
- Vironexis Biotherapeutics: vironexis.com: https://vironexis.com
- Vironexis Biotherapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06533579
- ClinicalTrials.gov: trials of VNX-101: https://clinicaltrials.gov/search?intr=VNX-101

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/), [CD3](https://onco.cc/targets/cd3/)
- companies: [Vironexis Biotherapeutics](https://onco.cc/companies/vironexis-biotherapeutics/)
- trials: [Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)](https://onco.cc/trials/nct06533579/)

---
JSON: https://onco.cc/api/v1/entities/vnx-101.json